5Dr. med. F. Rauhut,H. E. Clar,M. Bamberg,G. Benker,Prof. Dr. med. W. Grote. Diagnostic criteria in pituitary tumour recurrence—Combined modality of surgery and radiotherapy[J] 1986,Acta Neurochirurgica(3-4):73～78
1Yin X M, Oltvai Z N, Korsmeyer S J.BHI and BHZ do-mains of BCL-2 are equired for inhibition of apoptosisandheterodimerization with BAX. Nature, 1994, 369:321
2Bronner M P, Culin C, Reed J C et al. The bcl-2 pro-tooncogene and thegastrointestinal epithelied tumer pro-gression model. Am J Pathol, 1995, 146:20
3Karamitopoulou E, Perentes E, Tolnay M et al. Progno-lic significance of MIB-I,P53, and bcl-2 immunoreactivi-ty in meningiomas. Hum Pathol, 1998, 29:140
4Nakasu S, Nakajima M, Nakazawa T et al. Alteration ofbcl-2 and bax expression inembolized meningiomas.Brain Tumor Pathol, 1998, 15: 13
5Matyja E, Taraszewska A, Marszalek P. Necrosis and a-papatsis of tumor cells inembolized meningimas:histopathology and P53, Bcl-2, CD-68 immunohis-tochemistry. FoliaNeuropathol, 1999, 37:93
6Roess1er K, Dietrich W, Kitz K. Express of Bcl-2Onco-protein on tumor cells andtumor-infiltrating lymphocyles(TIL) in meningiomas. Neurosurg Rew, 1999, 22:205
7Ohta M, Twaki T, Kitamoto T et al. MIBI Staining in-dex and scoring of predictionof biologic potential andpostoperative management. Cancer, 1991, 74:3176
8Zuber F, Hamou M F, De Tribolet N. Identification ofproliferation cells in humanglioma using the monoclonalantibody Ki-67. J Neurosurg, 1998, 22:364
